Vertexs midstage data amplify kidney disease market opportunity

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 24 Sept, 12:07 UTC

Vertex has reported positive phase 2b data for its kidney disease prospect inaxaplin, boosting its efforts to expand beyond the population targeted in a pivotal trial.